. 2021 Sep 18;26(18):5677. doi: 10.3390/molecules26185677

Table 9.

In vitro agonist activities and antinociceptive of N-methylmorphinans 22, 1, 2 and 4, and their N-phenethyl substituted analogues 22b, 1b, 2b and 4b.

	In Vitro Agonist Activity ^a						Antinocieption ^b
	MOP		DOP		KOP		ED₅₀ mg/kg, s.c.
	EC₅₀ (nM)	% stim.	EC₅₀ (nM)	% stim.	EC₅₀ (nM)	% stim.	ED₅₀ mg/kg, s.c.
>Morphine (22)	34.4	89	668	109	710	76	3.06
22b	10.3	113	712	138	1049	19	0.11
Oxymorphone (1)	7.80	92	259	87	463	48	0.35
1b	2.67	97	131	101	225	7.5	0.15
2	1.21	95	38.5	102	135	65.9	0.014
2b	1.26	98	9.34	107	144	35.4	0.014
4	2.66	99	36.8	100	181	68.9	0.024
4b	1.86	102	9.54	103	334	51.3	0.024

^a Determined in the [³⁵S]GTPγS binding assays using CHO stably expressing human opioid receptors; percentage stimulation relative to the standard full agonists DAMGO (MOP), DPDPE (DOP) or U69,593 (KOP). ^b Determined in the tail-flick test in mice after s.c. administration. Data from [94,116]. For compound structures, refer to Figure 3.